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Cancer metabolism is characterized by an accelerated glycolytic rate facing reduced activity of 
oxidative phosphorylation. This “Warburg effect” represents a standard to diagnose and monitor 
tumor aggressiveness with 18F-fluorodeoxyglucose whose uptake is currently regarded as an accurate 
index of total glucose consumption. Studying cancer metabolic response to respiratory chain inhibition 
by metformin, we repeatedly observed a reduction of tracer uptake facing a marked increase in 
glucose consumption. This puzzling discordance brought us to discover that 18F-fluorodeoxyglucose 
preferentially accumulates within endoplasmic reticulum by exploiting the catalytic function of 
hexose-6-phosphate-dehydrogenase. Silencing enzyme expression and activity decreased both tracer 
uptake and glucose consumption, caused severe energy depletion and decreased NADPH content 
without altering mitochondrial function. These data document the existence of an unknown glucose 
metabolism triggered by hexose-6-phosphate-dehydrogenase within endoplasmic reticulum of cancer 
cells. Besides its basic relevance, this finding can improve clinical cancer diagnosis and might represent 
potential target for therapy.
In most solid cancers, the high needs of ATP and macromolecules for the rapidly growing biomass result in accel-
erated glycolysis facing relatively low rates of Krebs cycle and oxidative phosphorylation (OXPHOS)1. Although 
exploiting this “Warburg effect”2 already became a clinical standard to diagnose and monitor cancer aggressive-
ness by 18F-fluorodeoxyglucose (FDG) imaging, its underlying mechanisms remain elusive and, in particular, an 
open discussion still exists about the role of mitochondrial injury3.
Addressing this uncertainty, we were evaluating cancer metabolic response to OXPHOS inhibition by met-
formin (MTF). In our starting hypothesis, the severe respiratory impairment4,5 should have triggered a “Pasteur 
effect” enhancing glycolytic flux6. By contrast, we repeatedly observed a dose-dependent reduction in FDG reten-
tion in response to MTF that preceded a decrease in proliferation rate in different cancer cell lines, both in vitro 
and in vivo7–9.
According to a largely accepted kinetic model, uptake of FDG and 2-deoxyglucose (2DG) depicts overall 
glucose consumption because both analogues enter the cytosol through GLUT carriers, are phosphorylated by 
hexokinases (HK) and accumulate within the cytosol being false substrates for downstream enzymes channeling 
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glucose-6-phosphate (G6P) to glycolysis and pentose phosphate pathway (PPP)10–13. The decrease in FDG 
retention under MTF was thus interpreted as an index of reduced glucose consumption despite the OXPHOS 
impairment. This finding at least partially agreed with studies on cancer metabolism using the same radionuclide 
approach14,15. However, it profoundly disagreed with the marked increase in glycolytic flux documented in vitro 
by direct measurements of glucose consumption and lactate release under comparable MTF doses14,16.
Investigating the divergent MTF effects on FDG retention and glucose consumption brought us to discover 
that tumor FDG uptake is largely independent from overall glucose utilization and tracks a novel monosaccharide 
metabolism that is triggered by hexose-6-phosphate dehydrogenase (H6PD) within the lumen of endoplasmic 
reticulum (ER), is fueled by glucose at high rates and is strictly related to cancer growth and aggressiveness.
Results
Metformin affects cancer metabolism in vivo. In our previous studies, MTF effect on FDG uptake 
was tested in xenografts of breast cancer in athymic (nu/nu) mice8. Since immune/inflammatory pathways may 
influence biguanide anticancer potential17, we extended our evaluation to murine colon (CT26) and breast (4T1) 
carcinomas, subcutaneously implanted in the hip of immuno-competent BALB/c mice. In agreement with the use 
of non-diabetic models, body weight and serum glucose levels were not significantly affected at any time by the 
high drug dosage used (750 mg/kg per day)8,18 (Supplementary Table 1). Nevertheless, dynamic micro-PET imag-
ing showed a significant and persistent cancer metabolic response to MTF both at weeks #1 and #2 after tumor 
implantation (Fig. 1A,B). The relevance of this impairment was corroborated by the evident decrease in cancer 
growth rate during the whole study duration (Fig. 1C,D). Moreover, compartmental analysis of FDG accumula-
tion19 documented that MTF markedly decreased both average and total lesion glucose consumption at one and 
two weeks after implant of both CT26 and 4T1 cancer cells (Fig. 1E,F).
Figure 1. In vivo effect of metformin on tumor glucose consumption and cancer growth. CT26 and 
4T1 cells were subcutaneously inoculated in the hip of BALB/c mice (200.000 cells/mouse). Treatment with 
metformin (MTF) (750 mg/Kg die) started 48 hours after tumor implantation and was maintained throughout 
study duration. Animals were divided into four groups of seven mice each. Imaging was performed at week #1 
and week #2 after implantation using a dedicated micro-PET system. Panel (A) shows the parametric maps of 
representative mice untreated (CTR) or under MTF therapy, one week (PET#1) or two weeks (PET#2) after 
CT26 implantation. The same sequence is reported in panel (B) shows for representative mice implanted with 
4T1 cells. White arrows indicate the tumor mass. Panels (C,D) show average tumor volume expressed in mm3 
in the corresponding groups with untreated and MTF lesions being indicated as white circle and gray squares, 
respectively. Glucose consumption is represented as average value throughout lesion mass (in nMol x min−1 x 
gr−1 panel (E) or total disposal in the entire lesion volume (in nMol x min−1, panel (F) for CT26 group, while 
Panel (G,H) follow the same scheme for 4T1 animals. Both PET indexes of cancer glucose consumption were 
significantly lower in MTF (gray columns) with respect to untreated (white columns) animals. (*= p < 0.05; 
**= p < 0.01 vs corresponding controls).
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Figure 2. Direct MTF effect on glucose consumption and FDG uptake. Panel (A) shows the evident dose-
dependent increase in glucose consumption (expressed in μ Mol/106 cells per day) under MTF treatment in 
both CT26 (white columns) and 4T1 (black columns) cells. This behavior was paralleled by a progressive and 
dose-dependent decrease in FDG uptake (expressed as % of total administered radioactivity) in the same cell 
cultures (Panel B) All experiments were performed in triplicate. A similar discrepancy occurred when the 
experiment was repeated in a broad panel of cancer cell lines using a fixed MTF concentration (5mM). Besides 
4T1 CT26, this finding also applied to human models of non-small cell lung cancer (Calu-1), triple negative 
breast cancer (MDA-MB231) prostate cancer (LNCAP), neuroblastoma (IMR-32) and melanoma (LB24). This 
opposite response is represented in Panel (C) Data are reported as difference (MTF-control) divided by control 
value for glucose consumption (green columns) and FDG uptake (pink columns). Panel (D) displays gels (run 
under the same experimental conditions for each cell line) reporting the effect of 24 hours exposure to 5 mM 
MTF on expression of acknowledged determinants of FDG kinetics, i.e. uptake (GLUT1) and entrapment 
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Different kinetics of FDG and glucose in cancer. The standard PET approach for in vivo measurements 
of glucose metabolism indicated a minor role for immune and inflammatory mechanisms in cancer metabolic 
response to MTF. We thus hypothesized that the divergent drug effects on glucose consumption and FDG reten-
tion reported in the literature7,8,14,16, might actually reflect different metabolic fates for the two metabolites. To test 
this hypothesis, we first planned a series of in vitro studies to simultaneously measure FDG uptake and glucose 
consumption in the same cell culture. Since in our previous experience, MTF action on FDG uptake was inde-
pendent from glucose concentration, we tested the effect of different drug doses using a constant monosaccharide 
availability in the culture medium (11.1 mM)20. In both CT26 and 4T1 cell lines, MTF markedly increased glucose 
disappearance from supernatant and profoundly decreased FDG uptake in a dose-dependent fashion (Fig. 2A,B). 
To determine whether this puzzling discordance is a peculiar feature of studied murine cell lines, we extended 
this evaluation to a broad panel of human cancers of different origin (lung, breast, prostate, neuroblastoma and 
melanoma) using the maximal MTF dose devoid of evident cytotoxic effect (5 mM). In naïve cultures, this experi-
ment confirmed the expected, direct relationship between glucose consumption and FDG uptake (Supplementary 
Figure 1). However, it also confirmed the divergent response to MTF that increased glucose disappearance from 
culture medium on average to 161 ± 8% of baseline value (range 135–268%), while decreasing FDG uptake on 
average to 60 ± 5% of corresponding control values (range 88–38%) (Fig. 2C).
Technical analysis of tracer kinetics confirmed the metabolic nature of this paradox. On one side, thin layer 
chromatography ruled out any breakdown of free 18F−, documenting that ≥ 94% of supernatant radioactiv-
ity was actually FDG-linked without any difference in migration profile regardless drug presence or absence 
(Supplementary Figure 2). Similarly, the acknowledged determinants of FDG transport and phosphorylation did 
not respond to MTF. In fact, drug exposure left unaltered GLUT1 availability21,22 (Fig. 2D) and did not affect HKII 
expression (Fig. 2D), although it partially removed the enzyme connection with mitochondrial membrane7,8,23 
(Fig. 2E). Total HK activity was actually reduced in cell lysates of both CT26 (Fig. 2F) and 4T1 (Supplementary 
Figure 3). However, this effect applied to the same extent to glucose and its analogue FDG (in its non-radioactive 
form 19F-FDG) while affinity ratio for the two substrates remained stable at 0.71 ± 0.06 for both cell lines regard-
less exposure to MTF (Fig. 2F, Supplementary Figure 3).
Therefore, the ratio between cell production rate of G6P and FDG6P remained constant regardless increasing 
drug concentrations, indicating that trans-membrane transport and entrapment mechanisms could not explain 
the divergent response of FDG and glucose to MTF.
We thus hypothesized the presence of an escape pathway represented by the possible occurrence of FDG6P 
de-phosphorylation. The canonical enzyme responsible for this activity is G6P-phosphatase (G6Pase), a complex 
of multiple proteins anchored to ER lumen whose expression has been mostly characterized in liver, kidney and 
gut due to their homeostatic role in regulating blood glucose levels24,25. Actually, FDG6P is a recognized substrate 
for this enzyme whose activity explains the relatively low sensitivity of PET-FDG in hepatocellular carcinoma as 
the unique cancer type in which G6Pase has been described so far26.
G6Pase activity was well represented in cell lysates of both CT26 and 4T1, was comparable to the one of 
rat liver homogenates and displayed a similar affinity for G6P and 2DG6P, as an analogue of the radioactive 
FDG6P (Supplementary Figure 4A,B). However, MTF significantly and equally reduced G6P and 2DG6P dephos-
phorylation rate in both cell lines (Fig. 2G). This response was not caused by any drug interference on enzyme 
activity since MTF addition to lysates of untreated cells was ineffective (Supplementary Figure 4A,B); rather, it 
reflected a decrease in protein expression (Fig. 2D) reproducing in studied cancer cells the mechanism of MTF 
anti-hyperglycemic action in hepatocytes27. Accordingly, cell capability to dephosphorylate FDG6P was actually 
lowered by MTF, indicating that G6Pase could not account “per se” for the divergent drug actions on tracer reten-
tion and glucose consumption.
Endoplasmic reticulum and FDG uptake in cancer. Altogether, these findings suggested that FDG 
retention might not represent the simple product of transporter-mediated uptake and subsequent trapping 
by phosphorylation. Rather, it might reflect the activity of MTF-sensitive metabolic pathways competing with 
G6Pase for FDG handling. Actually, accumulation of FDG metabolites downstream FDG6P has been already 
described mostly in normal tissues of non-neuronal origin28, although this issue has been scarcely addressed in 
cancer.
G6Pase is located within the ER lumen24,27,29 in strict connection with another G6P-processing machinery 
governed by H6PD30,31. This autosomally-linked enzyme catalyzes the first two reactions of PPP within ER trans-
forming G6P into 6-phospho-gluconolactone/6-phospho-gluconate. Since its activity is remarkably lower with 
respect to its cytosolic counterpart sex-linked G6PD, H6PD is usually considered as a regulator of the signaling 
pathway tuning activation-inactivation of steroid hormones. This activity implies the supply of NADPH as a 
(HKII), in both 4T1 and CT26 cell lines. The drug even decreased G6Pase expression whose availability is 
warranted to allow FDG6P de-phosphorylation. This inhibition was paralleled by enzyme dislocation out 
from the mitochondrial membrane (Panel E,F) shows the moderate decrease of total HK activity in CT26 cell 
lysates (expressed as U x mg−1 of proteins, data for 4T1 are reported in Supplementary Figure 3). However, this 
response could not explain the divergent responses of glucose and FDG to MTF. In fact, cell lysate affinity ratio 
for glucose and nonradioactive FDG form 19F-FDG remained stable despite increasing drug concentrations. 
Panel (G) displays G6Pase enzyme activity on G6P (green) and 2DG6P (as an analogue of FDG6P, pink) in 
lysates of both CT26 and 4T1 cell lines (expressed as U × mg−1 of proteins). Dephosphorylation rate of both 
substrates was decreased to a similar degree by 24 hours exposure to 5 mM MTF indicating that drug-induced 
increase in tracer loss was not caused by a selective enhancement of G6Pase activity on glucose analogues.
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Figure 3. H6PD and glucose metabolism in cancer. Panels (A,B) display gels, (run under the same 
experimental conditions for each cell line), of H6PD and G6PD expression, evaluated with Western blot analysis. 
Quantitative analysis is reported in Panel (C), for both CT26 (white columns) and 4T1 (black columns) cells, 
respectively. Only H6PD gene silencing (siRNA) significantly altered enzyme availability. By contrast, G6PD 
expression did not respond to any treatment (Panel A,B,D), confirming different regulatory mechanisms for 
the two enzymes. Enzymatic activity (expressed as mU x mg−1 of proteins) displayed an obviously different 
response, since MTF, the indirect H6PD inhibitor carbenoxolone (CBX), and gene silencing significantly 
decreased H6PD function (Panel E) without altering the G6PD one (Panel F). Again, the effect was extremely 
similar for both CT26 (white columns) and 4T1 (black columns) lines. Panels (G,H) display the effect the 
different treatments on FDG uptake (pink columns) and glucose consumption (green columns) in the same cell 
lines. Scramble administration was virtually ineffective. On the contrary, glucose intake was increased by MTF 
while being reduced by both CBX and gene silencing by siRNA. This pattern faced a direct effect of all treatments 
that significantly reduced FDG uptake in the same cell cultures. These data thus document that H6PD triggered 
metabolism is fueled by glucose at high rate. * = p < 0.01; **p < 0.001 vs corresponding control.
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cofactor for the enzymatic function of 11-β − hydroxy-steroido-reductase32,33. However, its ubiquitous expression 
and its wide intracellular distribution31,34 suggest a housekeeping role in ER redox homeostasis.
Our interest in this enzyme was justified by its acknowledged capability to process a large number of substrates 
beyond G6P35. This concept was confirmed by our preliminary experiments in which, differently from G6PD, 
purified H6PD was able to oxidize not only G6P but also 2DG and 2DG6P (Supplementary Figure 4C,D), sug-
gesting a possible role for this enzyme in FDG6P processing. Actually, H6PD function was evident in both CT26 
and 4T1 lines, and its strict association with intracellular membrane30,32 was confirmed by the need of prolonged 
cell sonication to extract its full activity in both cell lines (Supplementary Figure 4E).
MTF did not alter the expression of both H6PD and G6PD (Fig. 3A–D). On the contrary, it selectively and 
markedly impaired H6PD catalytic function almost halving cell lysate capability to dehydrogenate 2DG6P in both 
cell lines (Fig. 3E) without affecting G6PD activity measured by G6P dehydrogenation rate (Fig. 3F).
H6PD and cancer glucose metabolism. This finding provided a preliminary possible explanation of 
the paradoxical divergence of biguanide action on FDG uptake and glucose consumption, indicating that tracer 
retention might reflect the accumulation of trapped metabolites downstream of H6PD-catalyzed reaction. To test 
this hypothesis, we evaluated cell response to 24 hours exposure to the carbenoxolone (CBX)33 that inhibits H6PD 
function by decreasing NADP+ supply by 11-β − hydroxy-steroido-reductase32,33. CBX did not affect expression 
of both H6PD and G6PD (Fig. 3A–D). However, it significantly and selectively reduced cell lysates capability to 
dehydrogenate 2DG6P as an index of H6PD catalytic function (Fig. 3E), again without altering G6P dehydro-
genation rate (Fig. 3F). These data are not surprising considering that the association between H6PD and CBX 
target 11-β − hydroxy-steroido-reductase32,33 was relatively preserved by our procedure that avoided the use of 
detergents in sample homogenization.
More importantly, CBX significantly reduced total glucose consumption to 74 ± 3% and 62 ± 3% of control 
values in CT26 (Fig. 3G) and 4T1 (Fig. 3H) cells, respectively. Interestingly, FDG uptake at least partially repro-
duced this response and decreased under treatment to 63 ± 5% and 27 ± 2% of control values in the same cell 
lines (Fig. 3G,H).
Obviously, both MTF and CBX recognize a number of targets related to energy metabolism4,5,36 that might 
interfere with FDG retention and glucose consumption through a series of mechanisms independent of H6PD 
catalytic activity. To overcome this limitation, we selectively inhibited H6PD gene expression, transfecting both 
CT26 and 4T1 cells with short interfering RNA (siRNA) or SilencerTM Negative Control #1 siRNA (scramble). 
H6PD silencing was able to reduce cell lysate capability to dehydrogenate 2DG6P to 13 ± 0.7% and 22 ± 1% of 
control values, in CT26 and 4T1 cells, respectively (Fig. 3E). The specificity of this action was documented by the 
ineffectiveness of scramble administration (Fig. 3E) while the absent response of G6P dehydrogenation activity 
confirmed a completely different regulation of the cytosolic enzyme G6PD (Fig. 3F).
H6PD silencing “per se” largely reproduced CBX action on both metabolic indexes. In fact, glucose consump-
tion – measured in the 24 hours after siRNA administration - was significantly reduced to 62 ± 3% and 60 ± 3% in 
CT26 and 4T1 cells, respectively (p < 0.001). More importantly, this effect paralleled the decrease in FDG uptake 
that fell to 73 ± 4% and 26 ± 2% of corresponding controls (p < 0.001), respectively (Fig. 3G,H).
Since the catalytic sites of both H6PD and G6Pase are located within the ER, the glucose analogues 2DG and 
FDG should selectively accumulate within this cell compartment. This issue is not trivial since the ionic nature of 
G6P and 2DG6P would indicate the possible involvement of specific carriers for trans-membrane transport37,38. 
Since affinity features and molecular characteristics of these proteins are largely unknown, we decided to verify 
whether 2DG6P actually accumulates within ER and whether the different treatments interfere with this locali-
zation. To this purpose, we used confocal microscopy to explore the intracellular distribution of the fluorescent 
2DG analogue 2-NBDG39 and its co-localization with respect to vital ER probes. Image analysis with appro-
priate software tool (ImageJ, NIH) documented that co-localization of 2-NBDG and ER was high in untreated 
or “scramble” cells and was markedly reduced by all treatments (MTF, CBX or H6PD-siRNA) providing an 
image-based documentation of ER role in glucose metabolism and FDG uptake in CT26 and 4T1 cells (Fig. 4).
H6PD and redox control of cancer biology. Differently from MTF, both pharmacologic H6PD 
impairment by CBX and selective silencing of its expression decreased overall glucose consumption of stud-
ied cancer cells suggesting an energetic role for ER metabolism independent from OXPHOS. This hypoth-
esis was strikingly confirmed. Actually, mitochondrial function was impaired by MTF that severely inhibited 
Complex I activity4,5 (Fig. 5A) causing a marked decrease in both oxygen consumption rate and ATP synthesis 
through pathway I-III-IV (Fig. 5B,C), despite a normal function of Complexes II-III-IV and their correspond-
ing pathways (Supplementary Figure 5A–C). However, both CBX and siRNA significantly reduced total ATP 
asset (Supplementary Figure 6A) and ATP:AMP ratio (Fig. 5D) without hampering mitochondrial OXPHOS 
(Fig. 5A–C, Supplementary Figure 5D,E). Degree of energy depletion caused by H6PD inhibition was actually less 
evident with respect to MTF. Nevertheless, its relevance was confirmed by the activation of the sensor mechanism 
AMP-activated protein kinase (AMPK)40 whose phosphorylation was comparably enhanced by all treatments 
(Fig. 5E,F, Supplementary Figure 6B,C).
The mitochondrion-independent and redox nature of ER glucose catabolism was corroborated by the analysis 
of the pyridine dinucleotides. In fact, NAD+/NADH ratio only decreased under MTF (Fig. 5G, Supplementary 
Figure 7). This response most likely reflected Complex I inhibition and resulted in an accelerated glycolytic flux 
with a consequent increase in lactate release (Fig. 5H). On the contrary, and in line with the expected response 
to H6PD inhibition, both CBX and siRNA selectively increased NADP+/NADPH ratio (Fig. 5I,J) confirming the 
role of this pathway in keeping ER redox balance in a reduced state. Moreover, despite a preserved NAD+ availa-
bility, both treatments significantly increased lactate release, indicating that complete glucose oxidation is at least 
partially independent from mitochondrial function (Fig. 5H).
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The fundamental role of H6PD-triggered glucose catabolism in cancer cell survival and growth was con-
firmed by the effect of enzyme interference on cell viability and proliferation rate. Actually, all treatments flattened 
growth curves of cell cultures (Fig. 6A–D). However, while siRNA selectively decreased proliferation rate, both 
MTF and CBX combined this cytostatic action with a significant cytotoxic effect (Fig. 6E–H). Finally, this biolog-
ical response closely agreed with the analysis of cell cycle distribution that displayed an evident block in G1 phase 
under all treatments (Fig. 6I,J).
Discussion
The divergent effect of MTF on glucose consumption and FDG uptake in cancer cells brought us to discover a still 
unidentified pathway for glucose utilization, largely autonomous from the well-recognized cytosolic glycolysis 
and PPP. This conclusion is first based on the evidence that retention of both FDG and 2DG reflects the activity 
of an ER processing machinery in which H6PD competes with G6Pase to process phosphorylated monosac-
charides. This pathway contributes to ER redox balance by preserving a low NADP+/NADPH ratio. However, 
it also contributes to maintain the whole cell energy asset since its inhibition decreases the ATP:AMP ratio and 
activates AMPK phosphorylation. Coherently with this role, H6PD-dependent pathway is fueled by glucose at 
rates approaching cytosolic carbohydrate utilization, since H6PD silencing results in a well measurable decrease 
in overall glucose consumption. These observations thus extend H6PD function far beyond its acknowledged role 
in signaling pathways related to NADPH-dependent activation of steroid hormones30–32,37.
So far, all current models of energy metabolism consider glucose consumption a well-established process 
managed by glycolysis and PPP. These data document, after more than 70 years, the existence of a further mech-
anism that, although still qualitatively uncharacterized, displays an activity close to the classical pathways. 
Moreover, both selective inhibition of H6PD enzyme activity and MTF similarly increased lactate release despite 
divergent effects on glucose consumption and, mostly, on NAD+ availability. These data thus indicate that ER 
metabolism contributes to the full conversion of glucose to water and CO2, at least in cancer cells. Together with 
the proteomic evidence of OXPHOS proteins within ER41, this finding suggests that control of ER redox state 
might be at least partially independent from mitochondrial function with both compartments contributing to cell 
energy asset through different pathways for glucose catabolism. The present data do not elucidate whether and 
how ER processing machine interacts with the most recognized cytosolic processes glycolysis and PPP. Similarly, 
they do not identify the mechanisms underlying its regulation. Finally, they do not clarify whether this metabolic 
Figure 4. Glucose analogue 2-NBDG accumulates within the ER. Confocal microscopy images of 2-NBDG 
fluorescence (green) and of vital probe ER-TrackerTM Red (ER) in CT26 cells. Merge row represents the 
readout of imageJ processing reporting the colocalized signal as white pixels. Co-localization between the 
two probes was quantified on original images acquired under identical detection conditions. Nevertheless, 
since 2-NBDG uptake was markedly diminished in MTF, CBX and siRNA treated cells, the green fluorescence 
was enhanced in the reported images. In control (untreated) cells co-localization accounted for 73 ± 8% of 
2-NBDG fluorescence as represented in the column chart at the bottom. ER entrapment of glucose analogue 
was markedly decreased by all treatments including 5 mM MTF, 180 μ M CBX and siRNA (** = p < 0.01). By 
contrast, scramble-RNA was virtually ineffective. These data thus confirmed the major role played by ER in 
entrapment of glucose analogue.
www.nature.com/scientificreports/
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Figure 5. Cancer energy asset. Panel (A) represents the function of mitochondrial respiratory Complex I in 
CT26 and 4T1 cell lines, respectively. MTF virtually abolished Complex I activity (expressed as mU x mg−1 of 
proteins) that was instead left unaltered by all remaining treatments. This effect resulted in a marked decrease in 
the rate of both oxygen consumption (expressed as μ Mol O2 x min−1 x mg−1 or proteins in Panel (B) and ATP 
synthesis (expressed as nMol x min−1 x mg−1 or proteins in Panel (C) through the pathway I-III-IV interrogated 
by pyruvate-malate administration. Despite this markedly different effect on OXPHOS, ATP:AMP ratio was 
significantly decreased also by CBX and siRNA (Panel D) though to a lower degree with respect to MTF. Panels 
(E,F) display the original gels, run under the same experimental conditions for each cell line, documenting 
the expected response of the energy sensor mechanism that caused an increase in p-AMPK without altering 
total AMPK levels. The redox nature of H6PD triggered metabolism was confirmed by the decrease in NAD+ 
availability, since NAD+/NADH ratio was selectively decreased by MTF (panel G). By contrast, lactate release 
(expressed as mMol/106 cells over 24 hours) was induced by all interventions but scramble (Panel H) despite 
an absent response of NADH levels. On the contrary, both CBX and siRNA, differently from the biguanide, 
increased the NADP + /NADPH ratio, without altering total coenzyme levels (measured in picoMol/106 cells) 
(Panels I,J). (*= p < 0.05; ** = p < 0.01 vs corresponding controls).
www.nature.com/scientificreports/
9Scientific RepoRts | 6:25092 | DOI: 10.1038/srep25092
Figure 6. Cancer biological response to energy depletion. Growth of both cell cultures was impaired by 
24 hours exposure to 5 mM MTF (red line) and CBX (blue line, at 180 μ M for CT26 and 135 μ M for 4T1) 
(Panel A,B) lines, with respect to untreated cell (green line). A similar, though delayed, effect was observed 
under H6PD gene silencing (black line) but not under scramble administration (green hatched line) in both 
CT26 (Panel C) and 4T1 (Panel D) lines. Cell growth reflected the contribution of cytotoxic and/or cytostatic 
effects of the different treatments. Viability analysis with Trypan blue (Panel E,F) demonstrated a significant 
increase in cell death caused by MTF (red columns) and CBX (blue columns) treatment (**= p < 0.01), while 
gene silencing (black columns) left virtually unaltered cell viability with respect to untreated (green columns) 
and scrambled (green hatched columns) conditions. By contrast, all treatments affected cell proliferation rate. 
In fact, CFSE analysis on the same cell cultures documented that mean fluorescence intensity (MFI), which is 
inversely related to cell proliferation, was lowered by all interventions (Panels G,H). This finding was confirmed 
by cell cycle analysis that documented a block in G1 phase under all treatments (Panel I,J). (*= p < 0.05; 
**= p < 0.01 statistical differences vs corresponding controls).
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pattern is universal or specific in cancer. To this purpose dedicated experiments would be needed to account for 
the effect of peculiar composition of culture media needed to warrant an adequate growth of “normal” cell cul-
tures. Nevertheless, the innovative nature of our findings challenges the currently accepted Warburg hypothesis 
of an accelerated glycolytic flux as the link between high glucose consumption and cell proliferation in cancer1.
These findings represent a paradigm shift in energy metabolism whose implications in cancer biology are 
far beyond our scopes. However, the present data “per se” display a great clinical relevance in the daily practice 
asking for PET/CT imaging in cancer patients. The model used in this setting has been mostly derived from 
studies on central nervous system while its application in normal tissues of different origin already asked for 
heuristic normalization factors, usually defined as “Lumped constant”, i.e. the ratio between FDG accumulation 
and glucose intake42–44. This factor is commonly attributed to the peculiar substrate affinity pattern of the different 
isoforms of HK and GLUT45 in the different tissues or under different conditions. The obligatory role of H6PD 
function and the lack of proportionality between tracer uptake and glucose consumption under MTF provide a 
new, alternative, explanation for the well-recognized direct relationship between FDG accumulation and cancer 
aggressiveness46,47. In this line, FDG uptake might be an index of H6PD activity and its link with cell proliferation 
more than a surrogate index of glycolysis rate in growing cancer. This novel clue has the potential to improve 
our comprehension of cancer evolution in patients and might represent the basis for a novel approach to explain 
the variability of lesion tracer uptake, in particular in those cancers usually unable to retain FDG despite a high 
glycolytic flux.
Materials and Methods
Chemicals. MTF was provided by Sigma-Aldrich (St. Louis, MO, USA). CBX was provided by Abcam 
(Cambridge, UK). FDG was produced according to standard methodology. Daily quality controls always docu-
mented a radiochemical purity ≥ 98%.
Cell lines and culture conditions. The murine cancer cell lines CT26 (colon) and 4T1 (breast) and the 
human cancer cell lines Calu-1 (lung), MDA-MB231 (breast), LNCaP (prostate) and IMR-32 (neuroblastoma) 
were purchased from ATCC (LGC Standards Srl, Milan, Italy). The human melanoma cell line LB24Dagi (LB24) 
was kindly provided by Dr. D. Castiglia (Istituto Dermopatico dell’Immacolata, Department of Molecular 
and Cellular Biology, Rome). All cancer cell lines were cultured at 37 oC under 5% CO2 in DMEM medium 
(Euroclone, Milan, Italy) supplemented with 1% L-glutamine, penicillin/streptomycin, nonessential amino acids 
and 10% fetal bovine serum (all from Sigma Aldrich). In all cases experiments were performed in triplicate, 
glucose concentration of administered medium was set at 11.1 mM. MTF treatments were performed for 24 h at 
concentrations ranging from 1 mM to 10 mM, while CBX was administered at 180 μ M for CT26 and at 135 μ M 
for 4T1 on the basis of preliminary assessment of IC50 dose.
Animal Models. All animal experiments were performed in accordance with guidelines and regulations 
(Italian 26/2014 and EU 2010/63/UE directives) and were thus approved by the Licensing and Ethical Committee 
of IRCCS San Martino-IST and by the Italian Ministry of Health. Six- weeks-old female BALB/c mice were 
purchased from Charles River Laboratories (Lecco, Italy) and housed under specific pathogen-free conditions. 
Animals were inoculated subcutaneously in the dorsal hip with 2 × 105 CT26 cells or 4T1cells. Each group was 
subsequently divided into four groups (two for each cell lines): “control” group (n = 7) and “MTF” group (n = 7). 
MTF was orally administered by diluting in autoclaved drinking water at a concentration of 3 mg/mL accounting 
for a dose of 750 mg/Kg/die8,18. Experimental protocol implied two imaging studies, at day #7 and day #14 from 
cell injection. Before each PET scan, mice were kept under fasting conditions for 6 h with free access to water. 
Cancer volume was determined by using external caliper and tumor volume was calculated using the following 
equation: tumor volume (mm3) = (length × width × height) × π /6, expressing length, width and height in mm. 
Mice were euthanized by CO2 asphyxiation at the end of experiments.
Experimental micro-PET scanning protocol. In vivo imaging was performed according to a protocol 
validated in our lab8,18. Mice were weighted and anesthesia was induced by intra-peritoneal administration of 
ketamine (100 mg/Kg) (Imalgere 1000, Milan, Italy)/xylazine (10 mg/kg) (Bio98 Srl, Milan, Italy). Serum glucose 
level was tested and animals were positioned on the bed of a dedicated micro-PET system (Albira, Carestream 
Inc, Rochester, MN, USA) whose two-ring configuration permits to cover the whole animal body in a single bed 
position. A dose of 3–4 MBq of FDG was then injected through a tail vein, soon after start of a list mode acquisi-
tion lasting 50 minutes.
Image processing. Acquisition was reconstructed using the following framing rate: 10 × 15 s, 5 × 30 s, 
2 × 150 s, 6 × 300 s, 1 × 600 s. PET data were reconstructed using a maximal likelihood expectation max-
imization method (MLEM). An experienced observer, unaware of the experimental type of analyzed mouse, 
identified a volume of interest (VOI) in the left ventricular chamber. Then, the computer was asked to plot 
the time-concentration curve within this VOI throughout the whole acquisition to define tracer input func-
tion. Further VOIs were drawn over cancer lesions to measure average metabolic rate of glucose per unit mass 
(MRGlu) was expressed in nM X min−1 X g−1; total lesion consumption was provided by the product MRGlu X 
(lesion volume) and was estimated in these last VOIs according to Gjedde-Patlak19 graphical analysis by using the 
routine of a dedicated software (PMOD, Zurich, Switzerland). Briefly, the software utilizes the input function to 
transform the original tissue activity measurements by fitting the data in each voxel with the slope of the regres-
sion line defined by the model. In all cases, lumped constant value was set at 1.
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Spectrophotometric Analysis. Glucose consumption was evaluated by monitoring supernatant concen-
tration throughout the 24 hours preceding the measurement of FDG uptake according to standard procedure48.
Enzymes activities were assayed on 50 μ g of total proteins as previously described7. Briefly, HK activity was 
estimated spectrophotometrically by following NADP at 340 nm, through a coupled reaction with G6PD. G6Pase 
activity was measured at 660 nm, following the inorganic phosphate production by the Fiske and Subbarow 
method. Capabilities to dehydrogenate G6P and 2DG6P (as indexes of G6PD and H6PD function, respectively) 
were evaluated in cell homogenates obtained with two different methods. In the former case, cells were sonicated 
two times for 10 s, with an interval of 30 s in ice; in the latter, cells were sonicated twice for 20 s, maintaining an 
interval of 30 s in ice. Detergents were never used in cell lysate preparation.
The medium lactate concentration was determined following the reduction of NAD+ at 340 nm. In all cases, 
metabolite absence in culture medium was tested48. The intracellular concentrations of ATP and AMP were meas-
ured, following the reduction of NADP and the oxidation of NADH, respectively, as previously described49.
FDG Uptake Evaluation. In all cases in vitro experiments were performed in triplicate. Cell culture was 
maintained at 37 °C for 60 minutes in a glucose free medium with FDG concentration set at 370 KBq/mL FDG, 
then the supernatant was collected and cells were recovered. Free and bound activities were thus simultaneously 
counted using a Packard Cobra II gamma counter (Packard, Meriden, CT, USA) with a 10% energy window 
centered at 511KeV. FDG retention was measured as the ratio between bound and total radioactivity. Labeling 
procedure did not affect cell viability.
Western blot analysis. Western blot experiments were performed accordingly to the standard proce-
dure with the following antibodies: anti-GLUT1, anti-HKII, anti-Phospho-AMPK (Cell Signaling, Danvers, 
MA, USA), anti-G6PD (Sigma Aldrich), anti G6Pase, anti-H6PD (Abcam) and anti-β-actin (Santa Cruz 
Biotechnology, Dallas, TX, USA).
Co-localization experiments. Intracellular localization of HKII was studied on cells cultured on glass cov-
erslips and treated with MitoTracker probe (Life Technologies Ltd, Monza MB, Italy), rabbit anti-HKII (C64G5) 
primary antibodies (Euroclone) and then with a goat anti-Rabbit Alexa Fluor 488 secondary antibody (Molecular 
Probes Eugene, OR, USA). Results were analyzed using an Olympus (Olympus Optical) laser-scanning micro-
scope FV500 equipped with an Olympus IX81 inverted microscope and Argon ion 488 nm, He-Ne 543 nm, and 
He-Ne 633 nm lasers. Digital images were acquired through a PLAPO 60× objective, with the Fluoview 4.3b soft-
ware program. Images were acquired sequentially as single trans-cellular optical sections. Spatial co-localization 
was analyzed by Image J 1.34f software (NIH).
Glucose metabolite distribution and co-localization with the endoplasmic reticulum (ER) were evaluated by 
confocal microscopy on live cells grown in glass-bottom dishes, stained for 15 minutes with the fluorescent probes 
2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxyglucose (2-NBDG) (50 microM ) and ER-TrackerTM 
Red (1 microM), both from Molecular Probes (InVitrogen, Eugene, OR), and analyzed by the SP2-AOBS confocal 
microscope (Leica Microsystems, Mannheim, Germany). Six to eight randomly selected fields containing at least 
8–10 cells were analysed in three independent samples for each treatment. Original unadjusted and uncorrected 
images were processed by ImageJ algorithms for the evaluation of colocalization, which was expressed as the per-
centage of above-background pixels in 2-NBDG images that overlapped above-background pixels in ER images, 
with background threshold set by the Costes’ method.
Oxygen consumption and ATP synthase assay. O2 consumption was measured at 25 °C in a closed 
chamber (1.7 ml capacity) using a thermostatically controlled oxygraph apparatus equipped with amperometric 
electrode (Microrespiration, Unisense A/S, Århus, Denmark) as previously described50.
ATP concentration was measured in a luminometer (Lumi-Scint, Bioscan) by the luciferin/luciferase chemi-
luminescent method48. In both cases, 5 mM pyruvate + 2,5 mM malate or 20 mM succinate were used as respiring 
substrates to assess the activity of the pathway formed by Complexes I, III and IV and the pathway composed by 
Complex II, III and IV, respectively.
Respiratory Complexes assay. The activity of the four respiring complexes was assayed on 50 μ g of total 
protein. Complex I (NADH-ubiquinone oxidoreductase) was assayed following the reduction of ferricyanide at 
420 nm50.
Complex II (Succinic dehydrogenase) activity was measured at 600 nm, in 2 mM EDTA, 0.2 mM ATP, 20 mM 
succinate, 0.5 mM cyanide, 80 μ M dicloroindophenol (DCIP), 50 μ M decylubiquinone, 40 μ M antimycin A, 
10 μ M rotenone and 10 mM phosphate buffer, pH 7.250.
To measure Complex III (Cytochrome c reductase) activity was followed the reduction of oxidized 
Cytochrome c, at 550 nm21. Finally, Complex IV (Cytochrome c oxidase) was assayed following the oxidation of 
ascorbate-reduced Cytochrome c at 550 nm50.
NAD+/NADH and NADP/NADPH determination. The ratio between NAD+:NADH and NADP:NADPH 
in cell lysates were evaluated spectrophotometrically, at 450 nm, using the NAD/NADH Assay Kit (Abcam: 
ab65348) and NADP/NADPH Assay Kit (Abcam: ab65349), respectively following the manufacture’s instructions.
Transfection assay. Silencing of H6PD expression was achieved by transfecting cells with H6PDH siRNA 
(Ambion siRNA ID 14371) or SilencerTM Negative Control #1 siRNA (Ambion, Huntingdon, Cambs, UK) both 
40 pMoles/ml, using Lipofectamine 2000 as transfection agent (2.5 microL/mL).
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Cell viability, proliferation and cell cycle analysis. Cell viability was evaluated by Trypan blue (Sigma Aldrich) 
exclusion test. To asses proliferation, cancer cells were labeled with 20 μ M CarboxyfluoresceinSuccinimidyl ester 
(CFSE) (InVitrogen) following the manufacture’s instructions. Samples were acquired in a Gallios cytometer 
(Beckman Coulter Spa, Cassina de’ Pecchi , MI) and analysed using Kaluza software. The percent of cells in G1, S 
and G2/M was determined by flow cytometer. Briefly cells were fixed in 80% ethanol, washed in PBS and stained 
with PI/RNase buffer. The acquisition and analysis were performed as previously described49.
Statistical analysis. The data are presented as mean ± standard deviation (SD). For comparison between 
different groups, the Null hypothesis was tested by analysis of variance (ANOVA) for multiple comparison; it was 
tested by Student t test for paired or unpaired data, as appropriate. Statistical significance was considered for p val-
ues p < 0.05. Statistical analyses were performed using SPSS software Advanced Models 15.0 (Chicago, Illinois).
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